Search Results - "Kasturi, Vijay" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

by Le Tourneau, Christophe, Hoimes, Christopher, Zarwan, Corrine, Wong, Deborah J, Bauer, Sebastian, Claus, Rainer, Wermke, Martin, Hariharan, Subramanian, von Heydebreck, Anja, Kasturi, Vijay, Chand, Vikram, Gulley, James L
Published in Journal for immunotherapy of cancer (22.10.2018)

Get full text

Journal Article

Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients

Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients

by Yorio, Jeffrey Thomas, Asnis-Alibozek, Aviva G, Kasturi, Vijay, Hutson, Thomas E
Published in BMC health services research (25.10.2024)

Get full text

Journal Article

673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

by Bauman, Julie E, Kasturi, Vijay, Birkhofer, Martin, Haddad, Robert
Published in Journal for immunotherapy of cancer (01.11.2023)

Get full text

Journal Article

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

by Keilholz, Ulrich, Mehnert, Janice M, Bauer, Sebastian, Bourgeois, Hugues, Patel, Manish R, Gravenor, Donald, Nemunaitis, John J, Taylor, Matthew H, Wyrwicz, Lucjan, Lee, Keun-Wook, Kasturi, Vijay, Chin, Kevin, von Heydebreck, Anja, Gulley, James L
Published in Journal for immunotherapy of cancer (16.01.2019)

Get full text

Journal Article

Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI

Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI

by Yorio, Jeffrey Thomas, Asnis-Alibozek, Aviva G., Kasturi, Vijay, Hutson, Thomas E.
Published in Journal of clinical oncology (20.02.2023)

Get full text

Journal Article

Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial

Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial

by Barata, Pedro C., Allman, Kim, Asnis-Alibozek, Aviva G., Kasturi, Vijay, Pal, Sumanta K.
Published in Journal of clinical oncology (01.06.2022)

Get full text

Journal Article

Final results of a phase 1b/2 study of tivozanib in combination with durvalumab in patients with advanced hepatocellular carcinoma in both previously untreated patients and patients progressing on atezolizumab and bevacizumab

Final results of a phase 1b/2 study of tivozanib in combination with durvalumab in patients with advanced hepatocellular carcinoma in both previously untreated patients and patients progressing on atezolizumab and bevacizumab

by Li, Daneng, Dayyani, Farshid, Mahalingam, Devalingam, Rowe, Julie Haewon, Abrams, Thomas Adam, Kasturi, Vijay, Iyer, Renuka V.
Published in Journal of clinical oncology (01.02.2023)

Get full text

Journal Article

A phase 1b/2, open-label study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive)

A phase 1b/2, open-label study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive)

by Dayyani, Farshid, Lee, Arielle Shebay, Li, Daneng, Rowe, Julie Haewon, Beg, Muhammad Shaalan, Kasturi, Vijay, Iyer, Renuka V.
Published in Journal of clinical oncology (01.02.2022)

Get full text

Journal Article

Phase 1b/2 study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive): Efficacy results in previously untreated patients

Phase 1b/2 study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive): Efficacy results in previously untreated patients

by Iyer, Renuka V., Li, Daneng, Dayyani, Farshid, Rowe, Julie Haewon, Beg, Muhammad Shaalan, Kasturi, Vijay, Abrams, Thomas Adam
Published in Journal of clinical oncology (01.02.2022)

Get full text

Journal Article

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial

by Barata, Pedro C, Chehrazi-Raffle, Alexander, Allman, Kimberly D, Asnis-Alibozek, Aviva, Kasturi, Vijay, Pal, Sumanta K
Published in The oncologist (Dayton, Ohio) (01.10.2023)

Get full text

Journal Article

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

by Choueiri, Toni K., Albiges, Laurence, McKay, Rana R., Pal, Sumanta K., Hammers, Hans J., Heng, Daniel Yick Chin, Beckermann, Katy, Kasturi, Vijay, Motzer, Robert J.
Published in Journal of clinical oncology (01.06.2022)

Get full text

Journal Article

Maturation of overall survival (OS) in TIVO-3 with long-term follow-up

Maturation of overall survival (OS) in TIVO-3 with long-term follow-up

by Rini, Brian I., Pal, Sumanta K., Escudier, Bernard, Atkins, Michael B., McDermott, David F., Verzoni, Elena, Porta, Camillo, Kasturi, Vijay, Hutson, Thomas E.
Published in Journal of clinical oncology (01.06.2022)

Get full text

Journal Article

Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel: Study informing treatment pathway decisions in Merkel cell carcinoma (MCC)

Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel: Study informing treatment pathway decisions in Merkel cell carcinoma (MCC)

by Bhanegaonkar, Abhijeet, Liu, Frank Xiaoqing, Kim, Ruth, Boyd, Marley, Fulcher, Nicole, Krulewicz, Stan, Kasturi, Vijay, Cowey, Charles Lance
Published in Journal of clinical oncology (10.10.2020)

Get full text

Journal Article

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

by Choueiri, Toni K., Albiges, Laurence, Hammers, Hans J., McKay, Rana R., Heng, Daniel Yick Chin, Beckermann, Katy, Kasturi, Vijay, Motzer, Robert J.
Published in Journal of clinical oncology (20.02.2022)

Get full text

Journal Article

$Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC$

Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC

by Atkins, Michael B., Verzoni, Elena, Escudier, Bernard, McDermott, David F., Hutson, Thomas E., Pal, Sumanta K., Porta, Camillo, Asnis-Alibozek, Aviva G., Kasturi, Vijay, Rini, Brian I.
Published in Journal of clinical oncology (20.02.2022)

Get full text

Journal Article

A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)

A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)

by Mahmood, Sharmeen, Li, Daneng, Lee, Arielle, Rowe, Julie, Beg, Muhammed, Kasturi, Vijay, Iyer, Renuka, Abrams, Thomas, Dayyani, Farshid
Published in Future oncology (London, England) (01.12.2022)

Get full text

Journal Article

Clinical impact of early progression among patients (Pts) with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs) in first-line (1L) setting: IMPACT RCC real-world study

Clinical impact of early progression among patients (Pts) with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs) in first-line (1L) setting: IMPACT RCC real-world study

by Hutson, Thomas E., Liu, Frank Xiaoqing, Pandya, Shivani, Dieyi, Christopher, Kim, Ruth, Krulewicz, Stan, Kasturi, Vijay, Bhanegaonkar, Abhijeet
Published in Journal of clinical oncology (20.05.2020)

Get full text

Journal Article

Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel –Study informing treatment Pathway dEcisions in Merkel cell cARcinoma (MCC)

Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel –Study informing treatment Pathway dEcisions in Merkel cell cARcinoma (MCC)

by Cowey, Charles Lance, Liu, Frank Xiaoqing, Kim, Ruth, Boyd, Marley, Fulcher, Nicole, Krulewicz, Stan, Kasturi, Vijay, Bhanegaonkar, Abhijeet
Published in Journal of clinical oncology (20.05.2020)

Get full text

Journal Article

Comparing progression-free survival (PFS) in second-line (2L) urothelial carcinoma (UC) treatments from single-arm trials: Importance of using appropriate methods

Comparing progression-free survival (PFS) in second-line (2L) urothelial carcinoma (UC) treatments from single-arm trials: Importance of using appropriate methods

by Kapetanakis, Venediktos, Prawitz, Thibaud, Schlichting, Michael, Ishak, K. Jack, Phatak, Hemant, Kasturi, Vijay, Yu, Ting, Bharmal, Murtuza
Published in Journal of clinical oncology (20.02.2020)

Get full text

Journal Article

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3

by Meza, Luis, McDermott, David F, Escudier, Bernard, Hutson, Thomas E, Porta, Camillo, Verzoni, Elena, Atkins, Michael B, Kasturi, Vijay, Pal, Sumanta K, Rini, Brian
Published in The oncologist (Dayton, Ohio) (17.03.2023)

Get full text

Journal Article